Company Overview and News

 
Comet Resources in an ASX trading halt

2017-06-21 proactiveinvestors.com.au
Comet Resources (ASX:CRL) has been granted a trading halt by the ASX, with its shares placed in pre-open.

 
Comet Resources eyes graphene from Springdale Graphite project

2017-05-31 proactiveinvestors.com.au
Comet Resources (ASX:CRL) has commenced drilling at its Springdale Graphite Project near Hopetoun in Western Australia to collect samples for further graphene metallurgical testwork.

 
Comet Resources drills up to 22% graphite from Springdale

2016-11-02 proactiveinvestors.com.au
The program consisted of four diamond drill holes for 282 metres and 103 aircore holes for 2,577 metres. The results for the first two diamond drill holes have been received: - 15.6 metres at 9.9% TGC (total graphitic carbon) from 30.4 metres including 7 metres at 20.8% TGC from 31 metres; - 8 metres at 9.9% TGC from 44 metres including 2 metres at 22.3% TGC from 44 metres. Comet has selected a number of drill samples for further test work.

 
Comet Resources Ltd intersects more graphite at Springdale project

2016-09-27 proactiveinvestors.com.au
Comet Resources Ltd (ASX:CRL) has completed a drilling program to define the strike extension of a newly discovered graphite zone at the Springdale project near Hopetoun in Western Australia. The company is awaiting assay results for the program which consisted of four diamond drill holes for 282 metres and 103 aircore holes for 2,577 metres. All four diamond holes intersected graphite mineralisation with widths over 10 metres.

 
Comet Resources Ltd looks to unlock graphite potential at Springdale project

2016-08-08 proactiveinvestors.com.au
Comet Resources Ltd (ASX:CRL) will conduct a drilling program primarily aimed at unlocking the graphite potential of the Springdale project near Hopetoun in Western Australia. The project is part of the Albany-Frazer Orogen which hosts the historic Halberts Graphite mine near Munglinup. The Munglinup area has produced the bulk of Western Australia’s recorded graphite production. Comet conducted first pass aircore drilling program at Springdale in February 2016, drilling a total of 11 holes for 324 metres.

 
Quarterly Activities Report

2016-04-22 asx.com.au

 
Quarterly Cashflow Report

2016-04-22 asx.com.au

 
Appendix 3B

2016-04-11 asx.com.au

 
Issue of Shares

2016-04-08 asx.com.au

 
Comet Resources Ltd makes graphite discovery in Western Australia

2016-04-06 proactiveinvestors.com.au
Comet Resources Ltd (ASX:CRL) has intersected graphite resources from first pass drilling at the Springdale project near Hopetoun in Western Australia, sending the share price flying. The discovery was within the southern margins of the Yilgarn Craton and constitutes part of the Albany-Frazer Orogen which hosts the historic Halberts Graphite mine near Munglinup. The results from the earlier drilling program included hits of: 10 metres at 9.

 
Comet Resources Ltd among ASX % Gainers intra-day

2016-04-06 proactiveinvestors.com.au
Comet Resources Ltd (ASX:CRL) is a diversified explorer focusing on gold and copper in New South Wales and Western Australia.

 
Details of Company Address

2016-03-16 asx.com.au

 
Half Year Accounts

2016-02-10 asx.com.au

 

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

16h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

17h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...